Overview

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Universitario Dr. Jose E. Gonzalez
Treatments:
Dasatinib